This Viral Travel Hack is Selling Out – Here's Why
Really, who hasn't had to sit on their suitcase when they pack a week's worth of clothes for a weekend trip and end up breaking the zipper of pricey baggage? Travel is already stressful without making things harder on yourself.
Ekster's space-saving travel solution has blown up on TikTok as travelers discover the key to easy packing – even for someone who needs to pack twelve pairs of shoes for a three-day vacation (if you know, you know).
So, how exactly does the TravelPack™ Vacuum Kit turn packing pain into packing pleasure? Easy: It allows users to compress their clothes, saving up to 60% of space in their luggage. Naturally, that makes the process more efficient and organized, cutting down on the expletives that often follow vacation prep.
It may seem complicated to figure out how to use vacuum packing bags, but it's quite simple. Once you finish packing and sealing the bag, you'll use a vacuum to suck out the air and maximize luggage space.
While Ekster began in the smart wallet industry, it quickly became a leader in both smart wallets and travel gear. Given that the company sold over 1 million smart wallets and amassed more than 50,000+ 5-star reviews, it's no surprise that it's ranked as the #1 bestselling trackable smart wallet brand globally.
With those accolades, travelers can rest assured that they're buying products they can trust. But for anyone who's still not convinced, Ekster offers free shipping and 100-day free returns. To boot, the company's GRID Backpack also won the 2024 iF Design Award, and co-founder Olivier Momma is a Forbes 30-under-30 recipient.
When it comes to travel perks, the TravelPack™ Vacuum Kit has more than the overflowing number of shirts you packed in your last suitcase. The product includes vacuum seal bags and a portable USB-C rechargeable air pump that provides 20 uses per full charge. The air pump compresses clothing, making it an ideal solution for travelers.
Of course, zippers can be the most finicky and unpredictable part of packing. Few things are as frustrating as one side of the zipper breaking away from the teeth. Ekster has travelers covered on that front with high-quality, anti-rip Nylon material and airtight, waterproof, and odor-proof zippers. If only suitcases provided that much support.
The carry-on-sized vacuum bags even have one-way valves to keep air from escaping. Even better? There's an alternative compression option that's compatible with any vacuum cleaner, and travelers can use the bags as laundry storage when they reach their destination.
You may be asking yourself about the benefits of compression bags vs packing cubes. The biggest difference is that compression bags offer a game-changing amount of space.
Wrinkled clothes are almost a guarantee when you overpack your suitcase, but the TravelPack™ Vacuum Kit can help them stay wrinkle-free and organized. For clumsy travelers known for spilling their iced coffee on luggage during a redeye, these travel vacuum bags also protect your suitcase's contents from spills and accidents.
Sometimes, checked bags are even pricier than the flight itself. By condensing everything in the TravelPack™ Vacuum Kit, travelers have a better chance of fitting all of the essentials into their carry-on while still having room to spare for anyone who can't resist a good gift shop (or ten). All in all, Ekster's TravelPack is more durable and reusable than cheaper options. The price is worth it in the long run, given how vacuum seal bags for clothes save money.
The TravelPack™ Vacuum Kit is changing how people pack, and its viral success proves travelers love the extra luggage space and stress-free process. With stock selling out fast, now is the time to grab the best compression bags for travel.
The kit is convenient and also allows travelers to save money, reduce stress, and approach trips with confidence. Smart solutions like Ekster's products demonstrate how innovative design can turn potentially frustrating experiences into moments of ease and anticipation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
27 minutes ago
- Forbes
Grown Brilliance Review: Lab Diamond Variety With A Sustainable Focus
Ethical luxury brand Grown Brilliance was founded in 2021 by Akshie Jhaveri, with the stated intention to offer high-quality, conflict-free diamonds to consumers. Just five years later, the brand boasts an impressive online selection and 14 retail locations across the country. While other lab-grown-diamonds-only retailers and brands sell both natural diamonds and lab versions, Grown Brilliance stands out for its laser focus on sustainability and transparency. We recommend them for their vast classic-meets-modern selection, accommodating service and bespoke jewelry design opportunity. Grown Brilliance creates lab grown diamond jewelry that's both classic and modern. ILLUSTRATION: FORBES / PHOTO: RETAILER As a quick primer, lab-grown diamonds are identical to mined diamonds in structure, chemistry and appearance. What this means: They have the same glorious sparkle, and no one—other than a well-trained gemologist with specialized tools—can easily tell the difference between a lab-grown diamond and a natural diamond. Grown Brilliance has the distinction of being a leader in the space, offering styles with cachet to industry experts and consumers alike. (For more on lab-grown diamonds, check out our stories on the best lab-grown diamond tennis bracelets and the best lab-grown diamond earrings.) Instead of being mined from the earth like natural diamonds—which are controversial due to their environmental and humanitarian impact—Grown Brilliance's ethically-sourced and conflict-free diamonds are created in a controlled lab environment. The process of crystallizing carbon atoms synthetically takes about two months, as opposed to the millions of years it takes naturally. (You can learn more about the nitty gritty of this process in our story on whether lab-grown diamonds are real, or on the Grown Brilliance web site.) Grown Brilliance offers diamonds that are GIA-certified and IGI-certified, which means they have been assessed and graded on cut, color, clarity and carat weight by the Gemological Institute of America (GIA) or International Gemological Institute (IGI). The brand's commitment to sustainability isn't limited to diamonds and gems. They use 96% recycled gold in their designs—which reduces the negative impact on the environment from mining—and they aim to use 100% recycled gold by the end of this year. They also use fully recyclable packaging and biodegradable materials in their packaging. Grown Brilliance has one of the largest collections of lab-grown diamonds that we've seen, including a variety of styles at different prices. They offer a wide selection of pre-designed engagement rings made with lab diamonds and gemstones, as well as sparkling studs for everyday, classic tennis bracelets and necklaces, sentimental anniversary bands and showstopping cocktail rings. The brand has nine different collections to choose from, including vintage-inspired jewelry (we love this elegant art deco ring), edgy, sculptural styles (like this serpent choker necklace) and sentimental, two-diamond styles (like this stunning and unexpected two-stone engagement ring). If you're interested in creating a personalized and unique lab diamond style—whether an engagement ring, necklace or earrings—you can work with Grown Brilliance's jewelers on a custom design through their site, much like if you walked into a jeweler's storefront. How it works: You upload a piece of inspiration to the site's portal, and you'll receive 3D renders of your design to modify or approve. You'll receive your custom piece in about 14 days. The brand also has boutiques in several cities if you'd like an in-person appointment. Favorable Shipping, Returns And Service Grown Brilliance offers free two-day shipping on all domestic orders—but not surprisingly, someone must be home to sign for your jewels. While some items are in stock and ready to ship, made-to-order items take about two weeks before they're sent out. If you receive an item and don't love it—and you should always love your jewelry, or what's the point?—you can return it for free within 30 days. Pre-designed pieces and Design Your Ring styles can be returned for a full refund, but bear in mind that special orders, high jewelry and Truly Custom orders can only be returned for store credit. All of Grown Brilliance's jewelry has a lifetime manufacturing warranty for all items, regardless of the price. The brand also has customer service agents available every day from 9 a.m. to 10 p.m. ET, so if you have a question or an issue, you won't have to wait ages for a response. Grown Brilliance offers financing, as well, through Affirm and Katapult. Why Trust Forbes Vetted Forbes Vetted's fashion editors have extensive experience writing about jewelry, often interviewing jewelry designers and gemologists. We have written stories on the best places to buy engagement rings, the best affordable jewelry brands and the best online jewelry stores. The writer for this story, Forbes Vetted fashion and beauty writer Molly Calhoun, has covered lifestyle topics, including fashion and accessories, for 20 years. Some of her recent work includes the best lab-grown diamond earrings and how to clean a diamond ring. Deputy editor Jane Sung , an industry veteran with over 20 years of experience reporting on jewelry and accessories, assigned and produced this story.
Business Upturn
an hour ago
- Business Upturn
Accelsius Brings NeuCool™ to Equinix's Co-Innovation Facility in Ashburn
AUSTIN, Texas, July 15, 2025 (GLOBE NEWSWIRE) — Accelsius, a leader in advanced data center cooling solutions, announced that its proprietary NeuCool™ IR80 system will be deployed in Q3 2025 at Equinix's Co-Innovation Facility (CIF) in the DC15 International Business Exchange™ (IBX®) data center at the Equinix Ashburn Campus. This dedicated facility provides a platform for Equinix to work with companies that are developing innovative technologies, helping customers see and experience these solutions in action. 'This kind of collaboration is a powerful way to demonstrate our technology in real-world scenarios,' said Josh Claman, CEO of Accelsius. 'The key thing we're finding with all the customers we're talking to is making it tangible to them—helping them see it and visualize how it's going to work for them. It's one thing to talk about technology and capabilities in the abstract, but this shows it in real time.' 'Liquid cooling is revolutionizing how data centers cool powerful, high-density hardware,' said Pawel Wlodarczak, Innovation Director, Global Design & Construction at Equinix. 'By working with companies like Accelsius in our Co-Innovation Facility we are able to help the industry continue to iterate and innovate on high density cooling solutions – such a critical aspect of the data center.' Accelsius' two-phase, direct-to-chip solution allows for 6–8°C warmer inlet water temperatures than other technologies. This warmer water temperature translates to significantly more free cooling and less reliance on energy-intensive compressors. This partnership brings together two companies committed to energy efficiency and was catalyzed by their shared participation in ARPA-E's COOLERCHIPS program, which aims to reduce total cooling energy use to below 5% of a data center's IT load. Beyond energy savings, Accelsius believes this deployment will also help showcase the benefits that two-phase, direct-to-chip cooling offers for customers' most valuable assets—GPUs. Unlike single-phase systems, Accelsius' dielectric fluid is non-conductive, ensuring no damage to electronics even in the rare event of a leak. About Accelsius Founded by Innventure, Inc. (NASDAQ:INV), Accelsius empowers data center and edge operators to achieve their business, financial and sustainability goals through advanced cooling solutions. The proprietary NeuCool platform provides best-in-class thermal efficiencies through a safe, two-phase liquid cooling system that scales from single racks to entire data centers. For more information, visit or follow us on LinkedIn. Media ContactTrebleMcKenzie Covell [email protected]
Business Upturn
an hour ago
- Business Upturn
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025 Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) ('Aquestive' or the 'Company'), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that Health Canada has granted the Company a meeting to discuss Aquestive's planned New Drug Submission (NDS) for Anaphylm™ (epinephrine) Sublingual Film in Canada. In addition, the Company has submitted an initial briefing book to the European Medicines Agency (EMA). The Company plans to submit a Marketing Authorization Application (MAA) to the EMA as soon as possible. 'These regulatory activities mark the pivotal first steps in Aquestive's comprehensive ex-U.S. regulatory strategy,' said Dan Barber, President and Chief Executive Officer of Aquestive. 'With our U.S. FDA New Drug Application recently accepted and a PDUFA target action date of January 31, 2026 established, we're now positioned to pursue parallel regulatory pathways with the potential to bring needle-free, device-free Anaphylm to patients underserved by current treatment options. Our proven ability to successfully bring innovative therapies to market globally, combined with our oral epinephrine approach, positions us to fundamentally change how patients and caregivers manage severe allergic reactions, including anaphylaxis.' Aquestive brings significant regulatory and commercialization experience to this expansion effort, with six FDA-approved drugs in its portfolio and products currently available across six continents. This established global footprint and regulatory track record positions the Company to efficiently navigate international approval processes. Unlike traditional epinephrine auto-injectors that require needles, Anaphylm™ is administered orally, addressing critical barriers to treatment, including needle phobia, device malfunction concerns, and portability challenges that affect patient compliance and emergency response. The Company's ex-U.S. regulatory strategy prioritizes markets with significant unmet medical needs and regulatory frameworks conducive to innovative therapies. EMA and Canada represent ideal initial international markets given their collaborative regulatory environment and substantial population of patients requiring reliable anaphylaxis treatment options. Aquestive will continue to provide updates on its global regulatory approval progress as it works to establish Anaphylm as the new standard of care for the treatment of severe allergic reactions and anaphylaxis worldwide. About Anaphylm™ (epinephrine) Sublingual Film Anaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. The Anaphylm trade name for AQST-109 has been conditionally approved by the U.S. Food and Drug Administration (FDA). Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate. About Aquestive Therapeutics Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions, including alopecia areata. For more information, visit and follow us on LinkedIn. Forward-Looking Statement Certain statements in this press release include 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'estimate,' 'intend,' 'may,' 'will,' or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA, Health Canada and EMA; the expected plans for regulatory approval and commercialization of Anaphylm in markets outside of the United States, if approved by the applicable regulatory authorities, including in Canada and the European Union; the advancement of the Company's product candidate AQST-108 through clinical development and approval by the FDA for possible various dermatology conditions including alopecia areata; the potential benefits our products and product candidates could bring to patients; and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm and AQST-108; risk of delays in advancement of the regulatory approval process through the FDA of our product candidates, including with respect to the approval of our filed NDA for Anaphylm, or the failure to receive FDA approval at all for any of our product candidates, including Anaphylm and AQST-108; risk of the Company's ability to generate sufficient clinical data for approval of our product candidates, including with respect to our pharmacokinetic and pharmacodynamic comparability submission for FDA approval of Anaphylm; risk of the Company's ability to address the FDA's comments on the Company's clinical trials and other concerns identified in the FDA's Type C meeting minutes and filing review letter for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risk that the FDA may require that an Advisory Committee be required for the approval of Anaphylm and that the Company is able to address any concerns raised by such Advisory Committee or the FDA after review of the advice from the Advisory Committee; risk of delays in advancement of the regulatory approval process outside the U.S. of our product candidates, including Anaphylm in Canada and the European Union; risk of the success of any competing products, including generics; risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of sufficient capital and cash resources, including sufficient access to available debt and equity financing, including under our ATM facility, and revenues from operations, to satisfy all of our short-term and longer-term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund commercialization activities relating to fund future clinical development and commercial activities for our product candidates, including Anaphylm and AQST-108, should these product candidates be approved by the FDA, Health Canada and EMA; risk of eroding market share for Suboxone® and risk as a sunsetting product, which accounts for the substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance in and outside of the U.S. of Anaphylm and our other product candidates, should these product candidates be approved by the FDA, Health Canada and EMA, and for our licensed products in the U.S. and abroad; risk of the size and growth of our product markets; risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to our products; risk that our patent applications for our product candidates, including for Anaphylm, will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office (USPTO); risk of unexpected patent developments; risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and products candidates and product pricing, reimbursement or access therefor; risk of loss of significant customers; risks related to claims and legal proceedings against Aquestive including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; risk of product recalls and withdrawals; risks related to any disruptions in our information technology networks and systems, including the impact of cybersecurity attacks; risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; risk of adverse developments affecting the financial services industry; risks related to inflation and rising interest rates; risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on our business; risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions; risks related to uncertainties about U.S. government initiatives and their impact on our business, including imposition of tariffs and other trade restrictions; and other unusual items; and other uncertainties affecting us including those described in the 'Risk Factors' section and in other sections included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners. Investor Contact:Brian Korbastr partners [email protected]
